At 104 weeks (2 years), patients in this subgroup reached 30.3% average weight loss confirming that retatrutide doesn't plateau at the primary endpoint and continues to improve with extended treatment
There's also evidence that GLP-1 agonists, like semaglutide and tirzepatide sold as Mounjaro, Ozempic, Wegovy and Zepound lower the risk of cardiovascular diseases protect the kidney and the liver, reduce inflammation and pain, prevent addiction and substance abuse, help people with arthritis and those with sleep apnea
Instant Convenience: Convenient to carry, ready to eat, with 120 gummies per bottle, your fingertips have 40 days of supply, and you only need 3 gummies per day
Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist administered as a once-weekly subcutaneous injection for type 2 diabetes mellitus